HIV positivity may not have a negative impact on survival in Epstein‑Barr virus‑positive Hodgkin lymphoma: A Japanese nationwide retrospective survey

  • Authors:
    • Mihoko Yotsumoto
    • Yoshikazu Ito
    • Shotaro Hagiwara
    • Yasuhito Terui
    • Hirokazu Nagai
    • Yasunori Ota
    • Atsushi Ajisawa
    • Tomoko Uehira
    • Junko Tanuma
    • Kazuma Ohyashiki
    • Seiji Okada
  • View Affiliations

  • Published online on: July 11, 2018     https://doi.org/10.3892/ol.2018.9132
  • Pages: 3923-3928
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There has been no comparative clinical study focused on differences in the clinical features of Epstein‑Barr virus (EBV)+ Hodgkin lymphoma (HL) between HIV‑positive and ‑negative cases. In a nationwide survey from 511 institutions in Japan, the present study investigated 16 EBV+ HIVpositive HL patients. To further clarify their characteristics in comparison with EBV+ HIVnegative HL (n=34) in the combination antiretroviral therapy era in Japan, the present study was performed. Results indicated that EBV+ HIVpositive HL frequently occurred in a younger population compared with EBV+ HIVnegative HL (P=0.0295), and that the EBV+ HIVpositive HL group was not associated with the nodular sclerosis subtype in the population who were below the age of 40. Notably, the EBV+ HIVpositive HL group had a significantly higher frequency of extra‑nodal involvement (P=0.0214), including marrow invasion. In the advanced stage, 80% of those with EBV+ HIVpositive HL did not require dose‑reduction and in the majority of cases, chemotherapy was completed. There were no significant differences in the complete remission rate (P=0.1961), overall survival (P=0.200) and progression‑free survival (P=0.245) between EBV+ HIVpositive HL (median observational period, 23.5 months) and EBV+ HIVnegative HL (median observational period, 64.5 months), suggesting that HIV positivity may not have a negative impact on the clinical outcome of EBV+ HL. Notably, standard chemotherapy is effective and tolerable for EBV+ HL, regardless of HIV infection.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yotsumoto M, Ito Y, Hagiwara S, Terui Y, Nagai H, Ota Y, Ajisawa A, Uehira T, Tanuma J, Ohyashiki K, Ohyashiki K, et al: HIV positivity may not have a negative impact on survival in Epstein‑Barr virus‑positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. Oncol Lett 16: 3923-3928, 2018
APA
Yotsumoto, M., Ito, Y., Hagiwara, S., Terui, Y., Nagai, H., Ota, Y. ... Okada, S. (2018). HIV positivity may not have a negative impact on survival in Epstein‑Barr virus‑positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. Oncology Letters, 16, 3923-3928. https://doi.org/10.3892/ol.2018.9132
MLA
Yotsumoto, M., Ito, Y., Hagiwara, S., Terui, Y., Nagai, H., Ota, Y., Ajisawa, A., Uehira, T., Tanuma, J., Ohyashiki, K., Okada, S."HIV positivity may not have a negative impact on survival in Epstein‑Barr virus‑positive Hodgkin lymphoma: A Japanese nationwide retrospective survey". Oncology Letters 16.3 (2018): 3923-3928.
Chicago
Yotsumoto, M., Ito, Y., Hagiwara, S., Terui, Y., Nagai, H., Ota, Y., Ajisawa, A., Uehira, T., Tanuma, J., Ohyashiki, K., Okada, S."HIV positivity may not have a negative impact on survival in Epstein‑Barr virus‑positive Hodgkin lymphoma: A Japanese nationwide retrospective survey". Oncology Letters 16, no. 3 (2018): 3923-3928. https://doi.org/10.3892/ol.2018.9132